Beta4-adrenoceptors are more effective than beta1-adrenoceptors in mediating arrhythmic Ca2+ transients in mouse ventricular myocytes

Naunyn Schmiedebergs Arch Pharmacol. 1999 Oct;360(4):445-56. doi: 10.1007/s002109900075.

Abstract

Putative beta4-adrenoceptors mediate cardiostimulation and arrhythmias in mammalian heart. Both beta1- and putative beta4-adrenoceptors mediate arrhythmias but through different mechanisms. To elucidate further the mechanisms of cardiostimulation and arrhythmias we measured Ca2+ transients and L-type Ca2+ currents in mouse ventricular myocytes. We used (-)-CGP 12177, an antagonist of beta1- and beta2-adrenoceptors with agonist properties at the putative beta4-adrenoceptor, and (-)-isoprenaline as an agonist for beta1- and beta2-adrenoceptors. (-)-CGP 12177 increased Ca2+ transients in electrically stimulated cells loaded with Indo-1. The maximum increase of Ca2+ transients caused by (-)-CGP 12177 amounted to approximately one-third of that caused by maximally effective (-)-isoprenaline concentrations. Both (-)-CGP 12177 and (-)-isoprenaline caused concentration-dependent arrhythmic Ca2+ transients. The arrhythmias appeared at paced Ca2+ transients and between paced Ca2+ transients. The arrhythmic potency of (-)-CGP 12177 (-logEC50=9.4) was approximately 40 times greater than that of (-)-isoprenaline (-logEC50=7.8). L-type Ca2+ current was measured in the whole cell configuration of the patch clamp technique. In the presence of both 3-isobutyl 1-methylxanthine (6 micromol/l) and (-)-propranolol (500 nmol/l), (-)-CGP 12177 (100 nmol/l) increased significantly L-type Ca2+ current by 19% of the effect of (-)-isoprenaline. The (-)-CGP 12177-evoked increase of Ca2+ transients contrasts with the smaller effects on L-type Ca2+ current, suggesting that activation of the putative beta4-adrenoceptor causes a more efficient Ca2+-induced Ca2+ release than activation of the beta1-adrenoceptor. Beta4-Adrenoceptors mediate arrhythmias with smaller Ca2+ transients and smaller increases of L-type Ca2+ current than beta1-adrenoceptors, in line with different but still unknown mechanisms as previously suggested for the intact heart.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Methyl-3-isobutylxanthine / pharmacology
  • Adrenergic beta-Agonists / pharmacology
  • Adrenergic beta-Antagonists / pharmacology*
  • Animals
  • Arrhythmias, Cardiac / metabolism*
  • Calcium / metabolism*
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Electric Stimulation
  • Heart Ventricles
  • In Vitro Techniques
  • Isoproterenol / pharmacology
  • Male
  • Mice
  • Patch-Clamp Techniques
  • Phosphodiesterase Inhibitors / pharmacology
  • Propanolamines / pharmacology*
  • Propranolol / pharmacology
  • Receptors, Adrenergic, beta / drug effects*
  • Receptors, Adrenergic, beta / physiology
  • Receptors, Adrenergic, beta-1 / drug effects
  • Receptors, Adrenergic, beta-1 / physiology
  • Time Factors

Substances

  • Adrenergic beta-Agonists
  • Adrenergic beta-Antagonists
  • Phosphodiesterase Inhibitors
  • Propanolamines
  • Receptors, Adrenergic, beta
  • Receptors, Adrenergic, beta-1
  • Propranolol
  • Isoproterenol
  • CGP 12177
  • Calcium
  • 1-Methyl-3-isobutylxanthine